Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific and manufacturing strengths to deliver innovative therapies to patients globally [3][4]. Investment Plans - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, enhancing AstraZeneca's capabilities in cell therapy and radiolabeled drugs [4]. - This commitment follows a previous investment of up to 2.5 billion USD announced in March 2022 for establishing a strategic R&D center in Beijing, marking AstraZeneca's second such center in China [3]. R&D and Product Pipeline - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [4]. - As of January 2024, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [4].

苏博科称，这笔超千亿元人民币的投资，开启了阿斯利康在华发展的新篇章。阿斯利康通过进一步扩展 在细胞治疗、放射偶联药物等突破性疗法的能力，将下一代创新疗法带给更多患者。通过这些投资，阿 斯利康在中国的员工规模将超过20000人。 阿斯利康是在中国市场销售额最高的外资药企，中国是阿斯利康在全球的第二大市场。在经历2024年的 公司治理风暴后，阿斯利康在2025年仍在加大对中国的投资。2025年3月初，阿斯利康宣布了一笔25亿 美元的投资计划(包括三项BD交易及一笔收购)，苏博科称这笔投资体现了阿斯利康对中国的坚定承 诺。 经济观察报记者张英 2026年1月28日至31日，英国首相基尔.斯塔默对中国进行正式访问，这是英国首相时隔8年再次访问中 国。 跨国药企阿斯利康全球首席执行官苏博科亦随团来华。1月29日，阿斯利康宣布，计划2030年前在中国 投资超1000亿元人民币(150亿美元)，以扩大在药品生产与研发领域的布局。 在2025年中国创新药火热的专利授权交易中，阿斯利康是最活跃的跨国药企，全年共出手5次，签下的 合同金额超100亿美元。其合作方包括石药集团(01093.HK)、和铂医药(02142.HK)、加科 ...

Group 1 - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030 to expand its presence in drug production and R&D [1] - The investment aims to enhance the company's capabilities in cell therapy and radiolabeled drugs, benefiting patients with cancer, blood diseases, and autoimmune diseases [1] - The investment will deepen AstraZeneca's R&D presence in China, including global strategic R&D centers in Beijing and Shanghai, which collaborate with over 500 clinical hospitals [1] Group 2 - The company will upgrade its production bases in Wuxi, Taizhou, Qingdao, and Beijing, with plans to announce new production facilities [1] - Existing facilities are currently providing innovative medicines to patients in China and over 70 global markets [1] - The investment is expected to increase AstraZeneca's workforce in China to over 20,000 employees and create thousands of new jobs in the healthcare ecosystem [1]

★ 宏观动态 ★ 央行：2025年第四季度全国新发放商业性个人住房贷款加权平均利率为3.06% 据央行消息，2025年第四季度全国新发放商业性个人住房贷款加权平均利率为3.06%。 国务院办公厅印发《加快培育服务消费新增长点工作方案》 国务院办公厅日前印发《加快培育服务消费新增长点工作方案》（以下简称《工作方案》），旨在优化和扩大 服务供给，促进服务消费提质惠民，为经济高质量发展提供有力支撑。《工作方案》提出3方面支持政策。一 是聚焦交通服务、家政服务、网络视听服务、旅居服务、汽车后市场服务、入境消费等重点领域，从优化服务 供给、推进先行先试、创新消费场景、加强人才培养等方面发力，激发发展活力。二是聚焦演出服务、体育赛 事服务、情绪式体验式服务等潜力领域，从健全激励机制、优化安全管理、培育优质品牌、建设平台载体等方 面着手，培育发展动能。三是通过健全标准体系、加强信用建设、强化财政金融支持等，加强对培育服务消费 新增长点的支持保障。《工作方案》要求各地区、各有关部门加强政策设计，创新支持举措，优化服务消费环 境，根据需要制定出台具体服务消费领域支持政策。 北京首个人形机器人中试验证平台正式启动，预计年产能50 ...

Group 1 - The core focus of Prime Minister Starmer's visit to China is on economic issues, marking a shift from previous years where political concerns dominated [1] - This visit is significant as it is the first by a UK Prime Minister in eight years, indicating a strategic choice to re-engage with China after a period of cooling relations [1] - The delegation accompanying Starmer includes key figures from the Treasury and major corporations such as HSBC and AstraZeneca, highlighting the importance of rebuilding economic ties with China [1] Group 2 - The UK is facing economic challenges post-Brexit, with a £22 billion fiscal gap and a need for growth, making engagement with China, the UK's fifth-largest trading partner, crucial [1] - The visit aims to establish mechanisms for cooperation, such as the revival of the UK-China CEO Council, focusing on sectors like green energy and digital economy [1] - A notable example of successful collaboration is the MG brand, which has thrived in Europe due to the partnership between UK and Chinese firms, demonstrating mutual benefits in technology and employment [1]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB (15 billion USD) in China by 2030 to expand its pharmaceutical production and R&D capabilities [1] Investment and Expansion - The investment will enhance AstraZeneca's research and development presence in China, including global strategic R&D centers located in Beijing and Shanghai [1] - These centers collaborate with over 500 clinical hospitals and have led numerous global clinical trials in the past three years [1] - The company will upgrade its existing production bases in Wuxi, Taizhou, Qingdao, and Beijing, with plans to announce new production facilities in due course [1] Employment and Economic Impact - Through these investments, AstraZeneca's workforce in China is expected to exceed 20,000 employees [1] - The initiative will create thousands of new jobs within the broader healthcare ecosystem [1]

(编辑：杨燕 林辰) （阿斯利康公众号） 1月29日，阿斯利康宣布，计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局。公司将充分发挥中国的科研优势和先进制造能力，并依托中英医疗健康生态系 统之间的协同合作，为中国及全球患者带来前沿创新疗法。 阿斯利康全球首席执行官苏博科表示，今天宣布的这笔逾1000亿元人民币的重大投资，开启了阿斯利康 在华发展的新篇章。中国已成为科学创新、先进制造和全球公共卫生领域的重要力量。通过进一步扩展 我们在细胞治疗、放射偶联药物等突破性疗法的能力，阿斯利康将为中国高质量发展作出更大贡献，更 重要的是，把下一代创新疗法带给更多患者。 ...

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to enhance its drug production and R&D capabilities, leveraging China's scientific research strengths and advanced manufacturing [1][3] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, aiming to bring China's innovative results to a global audience [3] - AstraZeneca's CEO highlighted that this investment marks a new chapter in the company's development in China, recognizing the country as a significant force in scientific innovation and global public health [3] Group 2: Strategic Initiatives - The investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline that benefits patients with cancer, blood diseases, and autoimmune disorders [3] - AstraZeneca aims to become the first multinational pharmaceutical company with end-to-end cell therapy capabilities in China [3] Group 3: Previous Investments - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - As of January this year, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [3]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: AstraZeneca on Thursday announced plans to invest $15 billion in China over the next five years as the global pharmaceutical industry increasingly looks to the country for innovation. The investments through the year 2030 will “span the value chain,” including drug discovery, clinical development and manufacturing, AstraZeneca said. The British d ...